Shining a Light on Dry AMD - How Photobiomodulation is Helping Dry AMD Patients
We will present an overview of photobiomodulation (PBM) therapy and will review current research on PBM in the treatment of dry AMD.
sponsored by Optos
Monday 29th March, 7pm BST
We will present an overview of photobiomodulation (PBM) therapy and will review current research on PBM in the treatment of dry AMD.
Valeda Light Delivery System is the first approved treatment for dry AMD using photobiomodulation. Valeda is a safe and effective, multi-wavelength PBM technology designed to improve visual acuity, improve contrast sensitivity and reduce central drusen volume.
Key discussion points:
- PBM mechanism of action
- Clinical data on the safety and efficacy of Valeda
- Case review and patient response to Valeda treatments
In the last couple of decades PBM therapy – a light-based treatment approach used widely for tissue repair and reducing pain and inflammation – has gained recognition among biomedical researchers and healthcare professionals. Now, LumiThera’s Valeda Light Delivery System is using a multi-wavelength PBM technology to treat ocular diseases and damage, aiming to help physicians address unmet patient needs.
Webinar Learning Objectives
- To understand the PBM mechanism of action
- To hear about clinical data on the safety and efficacy of Valeda
- To be presented with several case reviews and patient response to Valeda treatments
